RECENTLY ACTIVATED: EA4181 TRIAL FOR MANTLE CELL LYMPHOMA

Mantle cell lymphoma (MCL) is an aggressive form of lymphoma, and the optimal upfront treatment is still unknown. This phase II trial, led by Nina D. Wagner-Johnston, MD (Johns Hopkins), will compare three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib and evaluate how well each one works in treating patients with newly diagnosed MCL. Learn more.